skip to navigation skip to content
Search
 

Fellows & Associates in Entrepreneurship

Kerry Baldwin

Managing Partner, IQ Capital

Kerry, Managing Partner IQ Capital, has over 20 years of deeptech venture capital experience.

She is the Chairman of the British Private Equity and Venture Capital Association.

IQ Capital backs thought-leading deeptech founders at seed and early stage and can invest up to £30 million in their outperformers. Exits include to Google, Apple, Oracle and Facebook as well as several IPOs.

Kerry is an active contributor to best practice in venture capital and participates in policy formation through her work with the BVCA and participates in several notable committees relating to cohesion agendas relating to UK Science and Innovation.

Suranga Chandratillake

General Partner, Balderton Capital

Suranga is a General Partner at Balderton Capital. He was previously an entrepreneur and engineer.

Suranga was the founder and CEO of blinkx, the intelligent search engine for video, a company he led for eight years and took public.

Before blinkx, Suranga was an early employee at Autonomy corporation, where he ultimately served as the company’s US Chief Technology Officer in San Francisco.

Suranga read Computer Science at Cambridge. He is a Fellow of the Royal Academy of Engineering, serves on the Prime Minister’s Council for Science and Technology and was granted an OBE for his services to technology and engineering.

Peter Cowley

Angel Investor

Peter Cowley, a University of Cambridge graduate, founded and ran over a dozen businesses in technology and property over the last 40 years.

He has a portfolio of 75 angel investments with ten good exits and thirteen failures.

Peter is a board member of the Global Business Angel Network (GBAN), President Emeritus of the European Business Angel Network (EBAN), former chair of the Cambridge Angels and was UK Angel of the Year 2014. He is a Fellow in Entrepreneurship at Cambridge Judge Business School and is a public speaker on entrepreneurship and angel investing throughout the world.

Darrin Disley

CEO of Mogrify

Darrin is a renowned scientist, entrepreneur, angel investor and enterprise champion who has started, grown, or invested in over 40 startup life science, technology and social enterprises, raising $545 million USD in business financing and closing $700 million USD in commercial deals.

He is currently CEO of Mogrify, a rapidly growing UK biotech aiming to transform the development of regenerative cell and in vivo reprogramming therapies.

Prior to this he was CEO of Horizon Discovery Group for 11 years, during which he led the Company from startup through a $113 million USD IPO, and rapid scale-up powered by multiple acquisitions of US peer companies to become a global market leader in gene editing and gene modulation technologies.

He has been recognised nationally and internationally for his achievements in business and was recently awarded a lifetime Queen’s Award for Enterprise Promotion for his work in promoting enterprise across the UK and appointed OBE for his services to business and enterprise in the healthcare sector.

Anne Dobrée

Head of Cambridge Enterprise Seed Funds

Anne has worked in University technology commercialisation since 1999. Anne first joined the technology transfer team at the University of Cambridge in 2001, and has held a number of roles with Cambridge Enterprise and its predecessors including Head of Technology Transfer and Interim Director.

Anne joined the Seed Funds team in 2008 and was appointed Head of Seed Funds in 2011. During her time at CE, Anne has supported many early stage companies and served on the boards of Pneumacare, Cambridge CMOS Sensors, Aqdot and Cambridge Touch Technologies to name a few. Anne was a founding member of Praxis, the UK Technology Transfer Training Programme.

Away from Cambridge Enterprise, Anne has worked in technology transfer at Imperial College Innovations Limited, in pharmaceutical development at Evans Medical, and in pharmaceutical product training at Information Transfer. Anne holds a BSc in Medical Microbiology and a PhD in Immunology.

Shaun Grady

Senior Vice President, Business Development Operations, AstraZeneca

Shaun has global responsibility for Business Development Operations at AstraZeneca (AZ), leading the company’s transaction execution, due diligence and Alliance and Integration Management function including licensing and partnering, M&A, externalisation and divestments.

Shaun was appointed to his current role in 2013. Prior to this, he was Vice President, Strategic Partnering & Business Development (2010-13) and Vice President, Corporate Business Development (2006-10).

Shaun originally joined ICI as an attorney and held positions in the pharmaceuticals, petrochemicals, and legal departments. Following the demerger from ICI, he was appointed Assistant General Counsel, Corporate for Zeneca Group.

Shaun worked on the merger of Astra and Zeneca, the merger of Zeneca Agrochemicals with Novartis Agribusiness to form Syngenta, and the creation of Avecia. Shaun also worked on the acquisition of Cambridge Antibody Technology (CAT) and later MedImmune and led the acquisition of Amylin, and subsequent buy-out of Bristol-Myers’ Squibb’s interest in the AZ – BMS Diabetes Alliance. More recently Shaun led the transaction team for AZ’s global ADC collaborations with Daichi Sankyo for Enhertu and subsequently DS -1062.

Shaun has led AZ’s recent externalisation and divestment programme involving significant sell – side transactions with Pfizer, Aspen, Grunenthal, Cheplapharm, Atnahs, Juvise, Recordati and Covis.

Shaun is a Fellow in Entrepreneurship at Cambridge Judge Business School and a Fellow Commoner of Lucy Cavendish College, Cambridge. Shaun is also Chairman of the Board of Directors of Cambridge United Football Club, and a member of the Board at Cambridge Arts Theatre, Healx and Prostate Cancer Research Centre.

Based in Cambridge, Shaun enjoys rugby and football, and occasionally turns his hand to sports writing.

Tim Guilliams

Co-founder and Chief Executive, Healx

Tim is a tech entrepreneur from the Cambridge Cluster, passionate about using big data and AI to accelerate treatments for rare diseases. He is the Co-founder and Chief Executive of Healx, the AI-powered, patient-inspired tech company, accelerating the discovery and development of rare disease treatments at scale.

In this role, Tim has been listed in The Sunday Times Maserati 100 list of entrepreneurs in 2019, was featured in The Telegraph’s Tech 100 in 2019, and was named one of In Vivo’s 30 Rising Leaders in the Life Sciences in 2020. He was also named as ‘One to watch’ in The Telegraph’s Top 50 Most Ambitious Business Leaders in 2020.

Tim is also the Co-founder and Trustee of the Cambridge Rare Disease Network (CRDN). Prior to Healx and CRDN, he obtained his PhD at the University of Cambridge in the field of biophysics and neuroscience, developing nanobody technology for Parkinson’s disease. Before moving to Cambridge UK, Tim obtained an MEng in bio- and chemical-engineering from the University of Brussels.

Andrew Harter

Founder and Group CEO of RealVNC

Michael Hayman MBE DL

Co-founder, Seven Hills

Michael is an entrepreneur, broadcaster and author.

He co-founded the campaigns firm Seven Hills, hosts the podcast Change Makers, and co-authored Mission for Penguin.

Michael is Chairman of Entrepreneurs at the private bank Coutts and co-founded the national campaign for early-stage enterprise, StartUp Britain.

He is Honorary Professor of the Purpose Economy at the University of London where he also holds an honorary doctorate.

Michael is a member of the Advisory Council of the Royal Philharmonic Orchestra, a columnist for CityAM and contributing editor for Country & Town House.

Michael was awarded an MBE for services to enterprise, is a Deputy Lieutenant for Surrey and a Freeman of the City of London.

Rachel Hurst

Chief Operating Officer, Domino Printing

Tim Jones

Senior Adviser to the Trustees, Allia

Chief Executive of the Allia Social Enterprise Group until 2019. Tim now chairs City and Continental (Allia C&C) and is the Senior Advisor to Allia’s Trustees.

He has overseen a range of new thinking and new financing solutions to address social challenges including Employment Bonds, Housing Bonds and Retail Charity Bonds.

Also, since 2012, Chairman of food and fragrance ingredients maker Treatt, and, since 2020, Chairman of Tier 1 Joinery Contractor TMJ Interiors.

Tim is a Member of the Chartered Institute for Securities and Investments (MCSI) an Associate of the Chartered Insurance Institute (ACII) and serves on the Court of the International Bankers Livery Company.

Jack Lang

Serial entrepreneur and business angel

Jack is a serial entrepreneur and business angel. Interested in “computer science and how the brain works”, his undergraduate degree in mechanical sciences at Cambridge led to a computer science diploma and a spell as Demonstrator in the Computer Laboratory.

He left the University to found (with Professor Shon Ffowcs-Williams) the consulting company Topexpress, one of whose projects was designing some of the software for the BBC Microcomputer.

Jack co-founded Raspberry Pi. He was a founder of Netchannel, which was acquired in 1998 by ntl, where he became Chief Technologist. Before that he founded Electronic Share Information, acquired by E*Trade in 1995. He is author of The High Tech Entrepreneurs Handbook and teaches and examines courses in business studies, entrepreneurship and ecommerce for the University of Cambridge Computer Science Laboratory. He was Entrepreneur in Residence at the Centre for Entrepreneurial Learning.

Jack is a Bye-Fellow and Director of Studies in Management at Emmanuel College. He is a Fellow at Cambridge Judge Business School, Affiliate lecturer at the Department of Computer Science and Technology, Computer Lab, University of Cambridge.

A keen baker and a passionate cook, he is one of the founders of Midsummer House Restaurant. He has also been architect and champion of the Cambridge fireworks display for more than 25 years.

John Lee

Chairman, Cambridge Enterprise Investment Committee

John was CFO of DisplayLink, a market leading USB graphics software and semiconductor business, from 2011 to July 2020, when it was acquired by Synaptics.

Starting with Sinclair, in 1984, he has been actively involved in the Cambridge technology scene and has held senior management/investor roles in a number of startups, many of which have resulted in successful exits or IPOs.

For the past twelve years, John has been Chairman of the Cambridge Enterprise’s Investment Committee, which currently manages technology assets of circa £65 million and which has an enviable track record of both investment and exit.

Bina Mehta

UK Chair, KPMG

Bina is UK Chair at KPMG and leads the firm’s UK Emerging Giants practice, working with fast growth, scale up companies.

She qualified in the UK, was sent to India during the establishment of KPMG India and has more than 20 years international M&A and Restructuring experience in the UK, USA and Canada.

She is actively involved in the trade and investment agenda, supporting scale up clients to access to finance and growth via international trade opportunities.

Bina leads the firm’s relationship with the Department for International Trade and is a member of the Council for Investing in Female Entrepreneurs.

Dr Jane Osbourn OBE

Chair, Mogrify; and CSO, Alchemab Therapeutics

Jane is Chair of cell therapy company Mogrify and CSO of Alchemab Therapeutics. She was an early employee of Cambridge Antibody Technology, which became MedImmune, where she contributed to the development of phage display technology and to the discovery of eight marketed drugs.

Jane was Chair of the Board of Directors of the UK BioIndustry Association from 2015-2019, is a Director of Babraham Bioscience Technologies, Cambridge Enterprise, and is a member of the Crick Translational Advisory Group.

In 2019 she was awarded an OBE in the Queen’s birthday honours for services to drug discovery and development and was awarded the Scrip Lifetime Achievement Award for contribution to the pharma industry.

Andy Phillipps

Co-founder, Booking.com and early-stage investor

Jon Reynolds

CEO and Co-founder, SwiftKey

Jon Reynolds co-founded SwiftKey in 2008 and was CEO until its acquisition by Microsoft in 2016. SwiftKey is best known for its smart typing technology which learns from each user to accurately autocorrect and predict their most-likely next word, and features on more than 1 billion devices to date. Jon studied Physics at the University of Cambridge and prior to founding SwiftKey, worked as a civil servant in the British Government. He was awarded an MBE in 2016 for services to technology.

John Snyder

Blaise Thomson

CEO, Bitfount

Blaise is CEO of Bitfount, a platform for collaborative machine learning on data that is not directly accessible.

Prior to Bitfount, Blaise founded Vocal iQ, which sold to Apple in 2015 and led Apple’s Cambridge team and acted as Chief Architect for Siri Understanding until 2019.

Simon Thorpe

Managing Partner, Delta2020

Simon is an angel investor, entrepreneur, coach, mentor and NED to early-stage technology companies. He has invested in over 50 companies (with a third founded/run by women) achieving nine exits along with seven failures.

Simon is Managing Partner of Delta2020, Chair of Cambridge Angels, Cambridge Judge Business School Entrepreneurship Fellow, and UKBAA Angel Investor of the Year 2016/17

He is a University of Manchester (UoM) Innovation Factory NED, UoM mentor and Manchester Tech Trust member.

A member of Angel Academe supporting female entrepreneurs.

Simon is a sports and outdoor enthusiast, cyclist, skier, petrol/electric head, and traveller.

Simon is an active proponent of the digital economy empowering #digitalentrepreneurs.

William Tunstall-Pedoe

Technology entrepreneur and investor

William is an entrepreneur and angel investor with a focus on AI.

He founded voice assistant startup Evi which was acquired by Amazon and was then a key member of the team that defined, built and launched Alexa. He left in 2016.

William has over 65 angel investments and mentors AI and blockchain startups for the Creative Destruction Lab – an early stage incubator headquartered in Toronto.

William also wrote the AI software that created the anagrams in the Da Vinci Code and once got lots of press for calculating that 11 April 1954 was the most boring day in history.

Jamie Urquhart

Personal projects

Until recently Jamie was a Venture Partner with Pond Venture Partners, investors in early-stage companies in the fields of semiconductor, communication, wireless and software. His current interests are IoT and the development of embedded control systems.

He has a BSc from Bath University in Physics and Physical Electronics and started his career in analogue and digital chip design at Plessey Research (Caswell), Jamie left Plessey to join Acorn Computers in 1984 to start on the implementation of the ARM processor, later managing the VLSI Design team. Jamie was part of the founding team of ARM Holdings from its inception in November 1990 until November 2002.

At ARM he undertook a number of roles, including VP of Sales and Marketing, Chief Operating Officer when the company floated on NASDAQ and the LSE, and latterly Chief Strategy Officer. After ARM he was an angel investor, before joining Pond Venture Partners as a Venture Partner.

He has experience of working with public companies and startups in operational and non-executive roles. He chaired the ESCO Steering Group whose report in 2013 led to the formation of the ESCO Council.

Jamie is a Fellow of the IET and an Honorary Fellow (Entrepreneurship) of Cambridge Judge Business School.

Jason Wu

Managing Partner, InteBridge Capital

Dr Caroline Austin

Vice President, Head of Transactions, Business Development, AstraZeneca

Vincenzo Garzya

Head of Operations Portfolio & Alliances, Data Science and AI, AstraZeneca

Prior to his current role, Vincenzo was the Operation Officer and Chief of Staff for Enterprise Data & Analytics Programme, PMO director for Optimising Medical Evidence Generation Activities and Patient Centricity Excellence Director responsible for the strategic direction and delivery leadership of the overall capability programs to enable lifecycle teams to build patient value in R&D.

Following his passion for advancement of medicines for patients, before joining AstraZeneca, Vincenzo has led several projects at GlaxoSmithKline-UK in World Wide Business Development, in the Centres of Excellence for Drug Discovery, in Global Project & Portfolio Management and in Global Medical Affairs. Vincenzo has contributed to several patented inventions, successfully led the in-licensing of gene-therapy treatments and built the global strategy, operations and governance for externally sponsored research.

Vincenzo is a doctor in medicinal chemistry with an international project management accreditation and an MBA in strategic management.

Dr Andrew Lynn

Chief Executive Officer, Fluidic Analytics Limited

Jason Mellad

CEO and Co-founder, Start Codon

Jason is a scientist entrepreneur passionate about translating innovative technologies into better patient outcomes.

As CEO and Co-founder of Start Codon, a Cambridge based accelerator, he aims to identify and recruit the most disruptive healthcare startups worldwide, seed fund them and leverage the exceptional resources of the Cambridge cluster to de-risk and drive their success.

Previously he was CEO of Cambridge Epigenetix and Business Development Manager for Horizon Discovery’s diagnostics division. He also served as an associate at Cambridge Enterprise, the technology transfer office of the University of Cambridge.

Ed Newton-Rex

Product Director for Europe at TikTok

Ed Newton-Rex is an entrepreneur and musician. He founded Jukedeck, an AI music composition company, which provided AI music for video and other media, and was used to create more than a million pieces of original music; it won a Cannes Innovation Lion and TechCrunch Disrupt, and in 2019 was acquired by ByteDance, who own TikTok, where Ed is now Product Director for Europe.

Ed has been named one of Business Insider’s 30 most creative people in UK tech, and is a published composer, having written music for a number of choral groups and for theatre.

Sunil Shah

CEO, o2h Group

Sunil Shah is an entrepreneur having begun his career in the Life Sciences team at PA Consulting. He co-founded Oxygen Healthcare which was fully acquired by Piramal Enterprises (BSE: PEL) in 2013.

Since this time, Sunil has co-founded the o2h Group, this includes o2h Ventures, an HMRC approved ‘Human Health’ Knowledge Intensive EIS fund; o2h Discovery, a medicinal chemistry research services company and o2h Co-Work Labs, a 2.7 acre science park under development in South Cambridge.

Sunil has won the UKBAA Angel Investor of the year award in 2019 as well as the OBN Special Recognition Award for his significant contribution in the life sciences industry.

He serves on the Board of the BIA as well as Cambridge Angels. He is either Chairman, Non-executive Director, Board Observer or an investor in over 20 Biotech companies in the UK.

Sunil has a degree in Biochemistry from Keele and an MBA from Cambridge University.